Aliasger K. Salem | PhD, Senior Associate Vice President for Research, Lyle and Sharon Bighley Endowed Chair and Professor of Pharmaceutical Sciences, University of Iowa
Aliasger K. Salem | PhD, Senior Associate Vice President for Research, Lyle and Sharon Bighley Endowed Chair and Professor of Pharmaceutical Sciences, University of Iowa
Aliasger K. salem | phd, senior associate vice president for research, lyle and sharon bighley endowed chair and professor of pharmaceutical sciences, university of iowa
Biography
Aliasger K. Salem, PhD, is Senior Associate Vice President for Research at the University of Iowa and the Lyle and Sharon Bighley Endowed Chair and Professor of Pharmaceutical Sciences and Experimental Therapeutics in the University of Iowa College of Pharmacy.
Dr. Salem’s research focuses on drug and gene delivery, nanomedicine, vaccines and immunotherapy, regenerative medicine, ocular therapeutics, and nanotoxicology. His laboratory develops particle-based delivery systems and biomaterials designed to improve the localization, safety, and effectiveness of therapeutic agents. These technologies have been applied to cancer immunotherapy, infectious disease vaccines, tissue regeneration, and diseases of the eye.
He earned his bachelor’s degree in applied chemistry from Aston University and his PhD in pharmacy from the University of Nottingham in the United Kingdom. He subsequently completed postdoctoral training at the Johns Hopkins University School of Medicine before joining the University of Iowa in 2004.
Dr. Salem has authored more than 290 peer-reviewed publications and is an inventor on multiple patents. He is an elected Fellow of the National Academy of Inventors, the American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, the American Association of Pharmaceutical Scientists, and the Controlled Release Society. He has also helped establish startup companies focused on translating academic discoveries into new therapeutic products.
In his university leadership role, Dr. Salem works to strengthen interdisciplinary research, shared research infrastructure, innovation, entrepreneurship, and the translation of discoveries into benefits for patients and society.
Interview
NanoSphere: Tell us a bit about yourself—your background, journey, and what led you to where you are today.
Aliasger: One of the largest disconnects is that academic research and therapeutic development often optimize for different outcomes. Academic research appropriately values novelty and mechanistic insight. A therapeutic product, however, must perform reproducibly across different batches, manufacturing sites, clinical settings, and biologically diverse patients. A statistically significant result in a highly controlled model is important, but it is not sufficient. Delivery systems are also still too often treated as containers that can be selected after the therapeutic cargo has been identified. In reality, the cargo, carrier, route of administration, target tissue, disease biology, immune response, and manufacturing process form a single therapeutic system. Changing any one of these elements can alter efficacy, biodistribution, toxicity, stability, and clinical feasibility.
Another problem is comparability. Formulations may be described incompletely, evaluated with different dose metrics, or tested using models and endpoints that make meaningful head-to-head comparisons difficult. Some systems rely on specialized materials or laboratory processes that cannot be transferred or scaled easily. A lack of standardized reporting, validated potency assays, and shared reference materials makes it harder to determine whether one platform truly offers an advantage over another.
We need to design delivery systems with the eventual clinical and manufacturing requirements in view. This means defining critical quality attributes early, developing mechanism-relevant potency assays, understanding biodistribution and immune responses, evaluating stability, controlling raw materials, and considering scale-up before the formulation becomes locked in. It also means reporting methods with enough detail that other laboratories can reproduce the work.
The broader conceptual shift is to recognize that delivery is not a downstream technical problem. It is part of therapeutic design from the beginning. Earlier engagement among discovery scientists, formulation experts, clinicians, manufacturers, regulators, and patients would help close the gap between an exciting laboratory result and a therapy that can be used reliably in the real world.
Aliasger's references
- Salem Research Laboratory: https://salem.lab.uiowa.edu/
- Google Scholar: https://scholar.google.com/citations?user=yI9ON-UAAAAJ&hl=en
- Publication on ferroptosis in Fuchs Endothelial Corneal Dystrophy: https://pubmed.ncbi.nlm.nih.gov/34087583/
- NIH SBIR announcement:https://www.linkedin.com/posts/aliasger-salem-5b36aa13_sbir-nih-innovation-activity-7491240475056812036-JWpR

